ZEN Graphene Solutions - Next-Gen Health Technologies ROI Investor Presentation - Summer 2021

Page created by Theresa Salinas
 
CONTINUE READING
ZEN Graphene Solutions - Next-Gen Health Technologies ROI Investor Presentation - Summer 2021
ZEN Graphene Solutions
Next-Gen Health Technologies ROI

Investor Presentation – Summer 2021

TSXV: ZEN
OTCQB: ZENYF
ZEN Graphene Solutions - Next-Gen Health Technologies ROI Investor Presentation - Summer 2021
Next-Gen Health Technologies ROI

  TSXV: ZEN; OTCQB: ZENYF
  ~$250 million market capitalization (no debt)

  ZEN is a nanotechnology company focused on next-gen healthcare solutions:
      • Prevention: ZENGuard for PPE & indoor air quality markets
                                TM

      • Detection: Aptamer-based rapid detection
      • Treatment: Antimicrobial compound as a therapeutic and healthcare product

ZEN ROI Strategy
   • Returns from monetizing current market opportunities (ZENGuard )
                                                                      TM

   • Optimizing supply chain near term; full vertical integration longer term
                                                                                       2
   • Intellectual Property development with substantial scale and upside optionality
ZEN Graphene Solutions - Next-Gen Health Technologies ROI Investor Presentation - Summer 2021
Next-Gen Health Tech Why Nanotech/Graphene?
What is Nanotechnology?
•     Research and innovation conducted on atoms and molecules to create new and useful properties
What is Graphene?
•     A nanomaterial consisting of a single layer of carbon atoms arranged in a honeycomb lattice that has extraordinary properties

Why is it unique?
            Property                                                                                         How it Can Be Used

Extremely high surface Treat Disease – Transporting antimicrobial agents to target viruses, bacteria and fungi
  area-to-mass ratio   Protection Against Pathogens – Antimicrobial agent on PPE/air filters to reduce transmission; preventative medical use
    Impermeable to hydrogen         Water & Air Purification – Filters, H2O purification, desalination, gas storage, hydrogen generators, waste management

     200x stronger than steel       Building Materials Additive – Composite materials & alloys; additive to rubber, plastics, aluminum and concrete

Stretches to 120% of its original
                                    Polymer Additive – Coatings, additives and wearable technologies
              size
    10x thermal conductivity of
                                    Composite/Polymer Additive – Composite materials, polymers, coatings, concrete, heat sinks/spreaders
             copper

     1000x capacity of copper       Clean Energy - Longer battery life, faster charge times, semiconductors, solar

              Nanotechnology and graphene have enormous potential to make the world safer, cleaner and more efficient;
                                    ZEN’s focus is on innovative nanotechnology-enabled healthcare solutions
ZEN Graphene Solutions - Next-Gen Health Technologies ROI Investor Presentation - Summer 2021
Next-Gen Health Technologies ROI Strategy

                      What We Focus On                                                                Why It Matters

     Returns from Monetizing Our Current Opportunities                                                Cash Generation           TM

R                   Commercializing our current                    •   Significant need and demand for detection and ZENGuard -enabled solutions
                      intellectual property (IP)                   •   Generates cash flow to support future growth and creates shareholder value

                  Optimizing Our Supply Chain                                                       Production Execution
          Long-term vertical integration strategy focused          •   Ensures competitive, consistent and stable input for our proprietary graphene-based
O        on development of graphene production capacity,               solutions (i.e., graphite and graphene oxide for coating/compound production)
             supply agreements and our 100% owned                  •   A well-established supply chain, production processes and marketing presence in the
                  Albany Pure™ Graphite deposit                        gives us an extremely strong footing ahead of potentially tremendous market growth

                                                                                                   Future Growth Engine
                    IP - Building Our Portfolio                    •   There are numerous applications for nanotechnology. We need to understand the
I     Positioning ourselves to thrive by developing partnerships       most attractive and practical opportunities to ensure we allocate resources and
       and securing new IP in high-growth areas of healthcare          establish partnerships and develop IP in the right areas
                                                                   •   Protects our ability to serve high-growth markets with unique, proprietary solutions

                                                                                                                                                              4
R         Returns From Monetizing Current Opportunities
                                  TM
   ZENGuard Antimicrobial Coating
   •       We have developed a non-toxic, antimicrobial coating that is 99+% effective against numerous pathogens, including
           COVID-19. Initial testing completed at Western University’s BSL-3 ImPaKT facility; 98% effective after 108 days
   •       Successfully tested against bacteria and fungi as well, with results demonstrating greater than 99.9% efficacy based on
           ISO standards. Provides for significant opportunity beyond COVID-19
   •       Can be utilized on PPE, filtration media (HVAC filters) and other materials such as paper, cardboard etc. as a
           preventative ‘catch-and-kill’ mechanism. Global provisional patents filed

                      Target Market                                        Estimated Size                                                                     Where We Can Create Value
                                                                                                                                               TM
               Personal Protective                                                                                        •     ZENGuard on masks, gloves and other PPE to protect front-line workers,
                                                                              > US     $52B1                                    the public and reduce spread of pathogens (including and beyond COVID-19)
                Equipment (PPE)
                                                                                                                                               TM
                                                                              > US $66B2                                  •     ZENGuard on air filters to kill airborne pathogens in homes, schools,
                Indoor Air Quality                                                                                              hospitals and commercial/industrial spaces

1 Source: 2019 estimate per fortunebusinessinsights.com; over $90B in 2027
2 Source: 2020 global HVAC filter estimate of US $12.9B per fortunebusinessinsights.com;   2020 US furnace filter market estimated at US $21.3B per researchandmarkets.com. Management estimates US represents 40% of global furnace filter
demand for illustrative purposes only
                                                                                                                                                                                                                                              5
ZENGuard for PPE & Indoor Air Quality Markets
                        TM
R

Testing & Approvals
•   Confirmation from two independent testing organizations that our coating does not inhibit air flow rates
                            TM
•   Masks with ZENGuard successfully passed requirements as a level 1 Medical Device for ASTM Level 1,2 and 3 – the
    highest level for surgical masks
                                            TM
•   Third-party testing confirmed ZENGuard on masks did not lead to any shedding or skin irritation
•   Health Canada is reviewing the application as a priority item with a decision expected soon

Commercialization & Production
•   Agreements with Trebor Rx for a first-year minimum of 100M masks/filters and a minimum of 100M nitrile gloves
                     TM
    with ZENGuard
                                                                   TM
•   Significant interest from other potential partners for ZENGuard on PPE and air filtration products
               TM
•   ZENGuard production capacity (coated mask equivalent):
     • Current: ~32 million per month
     • Q4 2021-Q1 2022: ~800 million per month
•   Engineering company (Bantrel) engaged to design and source equipment for production at industrial scale

                                                                                                                      6
R           Disposable Mask Market Opportunity

Assumptions:                                                                                                                               Market Penetration and
•     1.5 trillion masks being used globally per year 1
•     We believe steady state demand could be ~60% of                                                                                   Gross Margin Scenario Analysis
      current need or ~930 billion                                                                                                                  (Illustrative Purposes Only)
                                                                                                                                                                                                             2,322   2,786
•     We assume gross margin per mask could range                                                                                                                                                1,393 1,858
      from $0.03 to $0.06                                                                                 $1,000                                                                      464 557
                                                                                                                                                            232 279           279 372

                                                                                           CAD Millions
                                                                                                                                                    139 186
                                                                                                           $100          37    46       56
Other Considerations:                                                                                              28
•     Secular shift in societal approach to PPE expected
      to support global demand above pre-pandemic                                                           $10
      levels (hospitality, food, janitorial etc.)
•     Governments seeking to build PPE reserves                                                              $1
•     Increase in aging population globally means a                                                                       0.1%                          0.5%                   1%                         5%
      higher number of higher-risk patients in the                                                                      (~930M)                        (~4.6B)               (~9.3B)                   (~46.4B)
      healthcare system and in public                                                                                                                 Market Penetration Scenarios
•     Emerging market usage represents significant                                                                                                  (% of global market and # of masks)
      growth opportunity
                                                                                                                                         $0.03            $0.04              $0.05         $0.06
                                                                                                                                         per mask         per mask           per mask      per mask

                                                                                                                                                                                                                             7
1 Source:   Estimate per ASC Publications “COVID-19 Pandemic Repercussions on the Use and Management of Plastics” (accessed Jan 2021)
R        Exam & Single-Use Glove Market Opportunity

Assumptions:                                                                                                Market Penetration and
•       585 billion gloves are needed globally per year 1
•       We believe steady state demand could be ~75% of                                                  Gross Margin Scenario Analysis
        current need or ~439 billion                                                                                 (Illustrative Purposes Only)
•       We assume gross margin per glove ranging from                             $1,000                                                                                              658 878
                                                                                                                                                                                439
        $0.01 to $0.04                                                                                                                                                    219
                                                                                                                                                         132 176
                                                                                                                                66 88               88

                                                                   CAD Millions
Other Considerations:                                                              $100                                    44                  44
                                                                                                                     22
•       Secular shift in societal approach to PPE expected                                          13 18
                                                                                                9
        to support global demand above pre-pandemic                                 $10    4
        levels (hospitality, food, janitorial etc.)
•       Governments seeking to build strategic PPE
                                                                                     $1
        reserves
•       Increase in aging population globally (higher                                            0.1%                      0.5%                    1%                              5%
        number of higher-risk patients in healthcare system                                    (~439M)                    (~2.2B)                (~4.4B)                        (~21.9B)
        & in public)                                                                                                      Market Penetration Scenarios
•       Emerging market usage represents huge growth                                                                 (% of global market and # of gloves)
        opportunity (Asia is ~80% lower than North
                                                                                                         $0.01               $0.02           $0.03            $0.04
        America today 1)                                                                                 per glove           per glove       per glove        per glove

                                                                                                                                                                                                8
1   Source: Ansell Oct 27, 2020 Capital Markets Day presentation
R        Indoor Air Quality Market Opportunity

                                                                                                                                           Market Penetration and
                                                                                                                                        Gross Margin Scenario Analysis
   Assumptions:                                                                                                                                        (Illustrative Purposes Only)
   •        Estimated 2020 air filtration market of US$66.3B1
                                                                                                                                                                                                                                    828 1,105
   •        Volume assumes average cost per filter of ~US$12                                                $1,000                                                                                                            552
                                                                                                                                                                                                                        276
                                                                                                                                                                                                     166 221

                                                                                             CAD Millions
                                                                                                                                                                    83 110                     110
                                                                                                             $100                                            55                           55
                                                                                                                                       22              28
   Other Considerations:                                                                                                   11
                                                                                                                                 17
   •        Secular shift in approach to air quality and safety –                                             $10     6
            especially for airborne viruses like COVID-19 –
            expected to support global demand above pre-                                                       $1
            pandemic levels (hospitals, schools, commercial,                                                                0.1%                              0.5%                                1%                           5%
            industrial, residential, air travel)                                                                          (~5.5M)                           (~27.6M)                           (~55.2M)                     (~276.1M)
                                                                                                                                                         Market Penetration Scenarios
                                                                                                                                                       (% of global market and # of filters)

                                                                                                                                          $1                      $2                  $3                   $4
                                                                                                                                          per filter              per filter          per filter           per filter

                                                                                                                                                                                     TM
                Actively exploring opportunities and partnerships to begin commercializing ZENGuard on air filtration media
1 Source:2020 global HVAC filter estimate of US $12.9B per fortunebusinessinsights.com; 2020 US furnace filter market estimated at US $21.3B per researchandmarkets.com. Management estimates a global furnace filter market of ~$53.3B assuming   9
the US represents 40% of global furnace filter demand for illustrative purposes.
R       Next-Gen Rapid Detection: How it Works

                Simple, affordable and accurate results without discomfort in under 10 minutes

             Binding, washing and buffer                          Sensor inserted              Acquire electric readout   Insert mobile   Result provided
             solution for sensor readout                            into mobile                       ~2 minutes           reader into
                         5-6 minutes                                   reader                                             smart phone

           ✓Next-Gen Technology: Newly developed, patent-pending DNA aptamer that recognizes SARS-CoV-2 spike protein
           ✓Speed: Many other rapid saliva tests require complicated and time-consuming separation, RNA extraction or
            amplification, have not been validated with clinical samples or require long assay times (> 1 hour)

                                                                                                                                                            10
Note: Process details will be refined as we optimize manufacturing, processing and results output
R       Next-Gen Rapid Detection: How It’s Different

                                  How We’re Different                                                                   Why it Matters
                                                                                          Affordability and less discomfort reduces testing aversion, allowing more frequent testing
                           Our simple and affordable, electric readout can provide a                  with fewer risks to other people compared to swab-based methods
  Why
            Scalability    rapid, single-step detection method with high sensitivity
                                                                                           Easier, Affordable Sampling + Less Discomfort + Fast, Accurate Results =
 Saliva?                      using a simple handheld reader and smart phone
                                                                                       enormous potential for widespread usage at home and in numerous public places

                          Extremely low detection limits (10,000-50,000 copies per ml)                       This has been a significant challenge for saliva-based testing to date

 What
                           Technology can be used as a platform for development of               Ability to detect new variants, other coronaviruses, viruses more generally –
happens      Solution                                                                               like the seasonal flu – and other pathogens using the same technology
                          new aptamers to detect new pathogens; new aptamers can
 post-      Longevity           be applied to sensors but use the same reader                   Our technology has the potential for significant value post-COVID
COVID?

                                                                                                                                                                                        11
R        Therapeutic Market Opportunity
                                                                                                                 Tony Mazzulli, MD, FRCPC, FACP
                                                                                                                 Microbiologist-in-Chief & Infectious Diseases Specialist
                                                                                                                 Professor, Depts. of Lab. Medicine & Pathobiology and Medicine, University of Toronto

 We have developed a patent pending graphene-based compound with 99.9% effectiveness against SARS-CoV-2
 and other harmful pathogens, including AMR organisms:
 ▪       Broad-spectrum compound 99.9% effective against viruses, bacteria and fungi – including four gram-positive and nine gram-negative
         bacteria with antimicrobial resistance
 ▪       Viricidal testing against SARS-CoV-2 completed at Western’s Biosafety Level 3 laboratory; antibacterial testing completed at McMaster
         University and Mount Sinai Hospital
 ▪       Testing revealed minimum inhibitory concentration < 1µg/ml to achieve 99.9% effectiveness
 ▪       Cytotoxicity results recorded no adverse effects on lab animals after seven days of repeated dosing at several thousands times higher
         than the MIC; no gross findings at necropsy
 ▪       Potential for upper/lower respiratory tract infections, digestive tract and topical for eyes, ears, foot care, wound care etc.
 ▪       ZEN is actively exploring other options to balance commercialization opportunities for our compound, taking into consideration many
         factors, including the size of the opportunity, potential partners, anticipated timeline and cost

                                                                                                                                              1
                                                                                                            > US $100B
                                                            (Total global market estimate for antibiotics, antiviral drugs and antifungal drugs annually)                                                      12
1 Source: 2020 antibiotic technologies   market per researchandmarkets.com (US$44M); 2019 antiviral market estimate per statista.com (US$52M); 2019 antifungal market estimate per bccresearch.com of US$14B
O   Optimizing Our Supply Chain – 2021 Roadmap

                                                                Upcoming Milestones
                                                              Current expectation; subject to change
                                             Q2                                      Q3                                          Q4

                     Graphite                                             Third-Party Purchases
            Current Supply & Procurement

                                                                                                                                                   Internal
                                                                                                                   Construction & Ramp-Up of       Capacity
                                                                                                                    Industrial Scale Capacity     Potentially
                 Graphene Oxide                                                                                                                    Available
            Procurement then Production                                                                                                             in 2022
                                                                    Third-Party Purchases As Needed

                               TM
                                                                          Current Pilot Capacity
                    ZENGuard                                                                                                                     Industrial scale
               Production & Spraying                                                                                                               capacity for
                                                     Engineering, Construction & Ramp-Up of Industrial Scale Capacity
                                                                                                                                                 production and
                                                                                                                                                   application
                                                                                                                                                Q4-2021/Q1-2022

✓ We will leverage currently available capabilities – supplemented by third-party purchases – to meet near-term demand for
            TM
  ZENGuard while we invest in our own internal capacity and integrate our supply chain
                                                                                                                                                           13
I     Intellectual Property – Building Our IP Portfolio
                    Developing partnerships and securing new IP in high-growth areas
      Graphene Enhancement Opportunity                                    Potential Benefits & Applications

                                         •   Other personal protective equipment (gowns, footwear etc.)
                            TM           •   Antimicrobial surface solutions for healthcare and for high-touch surfaces in public spaces
Prevention: ZENGuard                     •   Potential for antimicrobial packaging
                                         •   Potential for broad-based application for reducing risk of pathogen outbreaks

                                         •   Aptamer development for other viruses like the seasonal/swine/avian flu, norovirus, HPV
Detection: Aptamer Development           •   Aptamer development for bacterial testing like E. Coli and potentially others
                                         •   Potential for cancer marker detection in the future

                                         •   Topical application for psoriasis, acne, diabetic foot and other skin conditions
Treatment: Antimicrobial compound        •   Potential for ingestion for digestive tract pathogens like C. difficile
                                         •   Potential for intranasal and optic applications as well

                 Academia                                    Government                                        Corporate

                                                                                                                                           14
Next-Gen Nanomaterials – Catalysts

 • Prevention: Health Canada review of ZENGuardTM-enhanced masks
 • Prevention: Commercialization of ZENGuardTM coating for PPE markets (masks &
   gloves) & Indoor Air Quality market
 • Detection: Additional testing and discussions with potential partners for
   manufacturing, marketing and distribution of our leading-edge rapid detection solution
 • Treatment: Milestones related to our antimicrobial therapeutic
 • Future Pipeline: Continuing to develop high-impact healthcare applications

                                                                                            15
Next-Gen Nanomaterials ROI

      R•
                                                                              TM
           Expect H2 revenue and cash flow generation from ZENGuard

      O•
                                            TM
           Graphene oxide and ZENGuard production build out progressing

      I•   IP – Substantial upside and optionality in high-growth healthcare areas

ZEN ROI Strategy
   • Returns from monetizing current market opportunities (ZENGuard )
                                                                      TM

   • Optimizing supply chain near term; full vertical integration longer term
                                                                                       16
   • Intellectual Property development with substantial scale and upside optionality
Appendix
Forward Looking Statements

  This presentation contains "forward-looking information" within the meaning of applicable Canadian securities legislation and United States
  federal securities laws. Forward-looking statements include, but are not limited to, estimates and statements with respect to ZEN Graphene
  Solutions Inc. future exploration and development plans, objectives or goals, to the effect that ZEN Graphene Solutions Inc. or management
  expects a stated condition or result to occur, including the PEA, expected timing for release of sample analyses and a resource estimate, the
  expected uses for graphite or graphene in the future, and the future uses of the graphite from ZEN Graphene Solutions Inc. Albany deposit, the
  adequacy of ZEN Graphene Solutions Inc. financial resources, business plans and strategy, and other events or conditions that may occur in the
  future. Generally, forward-looking information can be identified by the use of forward- looking terminology such as “potential”, "plans", "expects",
  or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or
  "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be
  taken", "occur", or "be achieved". These forward-looking statements are subject to a number of assumptions, risks and uncertainties, many of
  which are beyond our control, which could cause actual results to differ materially from such forward-looking statements. As such, undue reliance
  should not be placed on these forward-looking statements. The forward-looking statements in this presentation are made as of the date hereof
  and ZEN Graphene Solutions Inc. disclaims any intention or obligation to update or revise any forward-looking statements in this presentation as a
  result of new information or future events, except as may be required under applicable Canadian securities legislation or applicable US federal
  securities laws.

                                                                                                                                                         18
Capital Structure

     TSXV: ZEN
     OTCQB: ZENYF

        Shared Issued    89,001,363                                     Expiry

                         1,305,155            @ $0.50              December 9, 2021

          Warrants       1,461,420            @ $0.80                July 6, 2022

                          867,598             @ $3.00                April 8, 2023

           Options       6,873,334    Avg. Weighted price: $1.22

         Fully Diluted   99,508,870

                                                                                      19
Leadership – Officers/Directors
Greg Fenton, (Chief Executive Officer, Director): is a seasoned investment professional, with a Bay Street career spanning nearly 30
years. He has worked in various capacities with ever-increasing responsibility in both the Canadian banking and investment management
sectors. Greg has been a partner in three investment management firms, heading the Risk Solutions Group at Scotiabank and leading
Liability Driven Investment Group at National Bank Financial. Greg currently leads a company providing balance sheet optimization and
investment services to Canadian and international corporations. His experience spans many disciplines: capital markets, investment
management, actuarial, pension, insurance, accounting, tax and risk management.

Dr. Francis Dubé, O. D., B. Sc. (Director and Executive Chairman): completed a Bachelor of Science at Waterloo, and then obtained
an Optometry degree at the Université de Montréal in 1997. Previously, as an entrepreneur, Dr. Dubé was a director and Co-founder of
Cannacure Corp., a private cannabis company that he saw to a successful buyout of $40 million. As a result of his role with Cannacure, Dr.
Dubé has gained significant experience in strategic planning, fundraising, and capital markets.

Brian Bosse, (Chief Financial Officer, Director): Brian has been a respected professional investor for nearly 30 years with corporate
capital allocation policy being his key business specialty. Formerly Brian served Dundee Corporation’s Goodman & Company Investment
Counsel as portfolio manager of the Goodman Bluespring Fund. He earned an honors degree from the Lazaridis School of Business and
Economics in Waterloo Ontario plus the Chartered Financial Analyst designation. Brian joined ZEN Graphene Solutions in May 2018 as
director and officer following a successful proxy battle.

                                                                                                                                             20
Rapid Test Market Overview                                                                           *

                                                                          Nasal                                                           Plasma                                          Saliva
                                                        Rapid PCR                               Rapid Antigen                         Rapid Antibody                            ZEN Aptamer-Based
                                                       (Abbott ID NOW)                             (Abbott Panbio)                     (BTNX Rapid Response)                       Antigen Test
                                                                                                                                                                                              1
  Sensitivity/Specificity %                              93.3/98.4                                  98.1/99.8                               94.6/100                                       82 /100

                           Speed                       < 13 minutes                                ~15 minutes                            ~15 minutes                                   < 10 minutes

                                       Testing equipment required; intended for                 Cassette, buffer,                                                           Cell phone, mobile electric reader,
                    Equipment           point-of-care use in healthcare settings                 collection tube
                                                                                                                               Cassette, buffer solution, lancet
                                                                                                                                                                             sensor, other components TBD
                                                                                                                 2                                       2
                             Cost               Equipment $4,500-$5,000                           $16 per test                            $19 per test                               Highly competitive

                                      Note: FDA regulations for sensitivity and specificity are ≥80% and ≥99%, respectively

                          We believe our combination of accuracy, speed, simplicity, scalability
                          and affordability is a differentiator based on what is available today
* Comparator data  represents a subset of publicly available information for a sample of commercially available rapid test products in Canada
1 Salivasamples for sensitivity tests were provided by hospitalized COVID patients – it is likely their samples contained spike-binding antibodies which inhibited aptamer binding. It is expected that sensitivity
would increase for a randomized clinical population, which is typically where less sensitive saliva-based rapid tests are expected to be less effective.
2 Per rapidtestandtrace.ca                                                                                                                                                                                            21
Rapid Detection Current and Future Demand

                    >2.6B                                                  $23.4B
     COVID Tests Administered Globally                    2020 Global Rapid Test Kit Market Estimate
             https://www.worldometers.info/coronavirus/           https://www.researchandmarkets.com/reports/5238566

 • Our experience during the pandemic has highlighted the importance of rapid, accurate testing
 • We expect this awareness will contribute to a secular trend supporting adoption of rapid
   testing and continued strong demand
 • By alleviating the aversion to testing associated with cost and the discomfort of nasal-based
   methods, we anticipate testing to become even more widespread further supporting demand
 • With more widespread testing and availability of data, we can reduce the transmission risk of
   COVID now, and many other pathogens in the future

We believe our technology will play a significant role in this compelling and enduring growth story
                                                                                                                       22
Optimizing Our Supply Chain – Overview
  Long-term vertical integration strategy focused on development of graphene production
     capacity, supply agreements and our 100% owned Albany Pure™ Graphite deposit

                                                                                                                      TM
                 Graphite Production                     Graphene Production                            ZENGuard & Compound                    Production of Graphene-
                                                                  (not exhaustive)
                                                                                                                                                 Enhanced Solutions
                                                                                                                                                             PPE
                                                                                                                                                             Air Filtration
                                                                                                                                                             Therapeutics

                                                         •   Graphene (varying # of layers)
Overview

            • Mined in several countries                 •   Graphene oxide (GO)                                                                            TM
                                                                                                                                               • ZENGuard applied to material and
            • Vast majority of graphite production is    •   Graphene nanosheets                        • Antimicrobial agents added to GO       provided to customer for final stage of
              metamorphic in origin vs. igneous, which   •   Graphene nanoplatelets
                                                                                                                                                 production and distribution
              exfoliates better (Albany Pure™)           •   Reduced GO
                                                         •   Graphene quantum dots
Our Focus

                                                                                                                                                                                   TM
            • Raw graphite mineralization from Albany    • Exploring development of GO capacity         • Engineering currently underway       • Evaluating options for ZENGuard
              available for refining                     • Patent on GO production method                 for industrial
                                                                                                                     TM
                                                                                                                         scale production of     application at our production
            • Exploring other options for additional     • 200 kg of GO in inventory; options for         ZENGuard at our Guelph, ON             facility in Guelph, ON
              supply, including third-party agreements     additional availability from third parties     facility
            • Environmental baseline study and
              permitting for our deposit to move
              toward extraction                                                                                                                                                         23
New Manufacturing Facility – Guelph, Ontario

         Newly constructed ~25,000 sq ft of B1
     1   industrial zoning in Guelph, Ontario

         3-year lease with 3-year option beginning
     2   February 1st, 2021

                                                     24
R&D Facility – Guelph, Ontario

  • Graphite purification and graphene production
  • Scaling up production capacity
  • Graphene products available for R&D and commercial use
  • R&D pipeline with interests in monomers, polymers,
    metal alloys, corrosion coatings, biosensors along with
    the production of graphene oxide and graphene quantum
    dots.

                                                              25
You can also read